100 related articles for article (PubMed ID: 10737750)
1. SH2-directed ligands of the Lck tyrosine kinase.
Lee TR; Lawrence DS
J Med Chem; 2000 Mar; 43(6):1173-9. PubMed ID: 10737750
[TBL] [Abstract][Full Text] [Related]
2. Recognition of a high-affinity phosphotyrosyl peptide by the Src homology-2 domain of p56lck.
Eck MJ; Shoelson SE; Harrison SC
Nature; 1993 Mar; 362(6415):87-91. PubMed ID: 7680435
[TBL] [Abstract][Full Text] [Related]
3. Effects of halogenation on tyrosine phosphorylation and peptide binding to the SRC homology 2 domain of lymphocyte-specific protein tyrosine kinase.
Okamura T; Kikuchi T; Nodaira M; Odaka K; Fukushi K; Irie T
Biol Pharm Bull; 2012; 35(3):433-7. PubMed ID: 22382333
[TBL] [Abstract][Full Text] [Related]
4. Identification of non-phosphate-containing small molecular weight inhibitors of the tyrosine kinase p56 Lck SH2 domain via in silico screening against the pY + 3 binding site.
Huang N; Nagarsekar A; Xia G; Hayashi J; MacKerell AD
J Med Chem; 2004 Jul; 47(14):3502-11. PubMed ID: 15214778
[TBL] [Abstract][Full Text] [Related]
5. L-O-(2-malonyl)tyrosine: a new phosphotyrosyl mimetic for the preparation of Src homology 2 domain inhibitory peptides.
Ye B; Akamatsu M; Shoelson SE; Wolf G; Giorgetti-Peraldi S; Yan X; Roller PP; Burke TR
J Med Chem; 1995 Oct; 38(21):4270-5. PubMed ID: 7473554
[TBL] [Abstract][Full Text] [Related]
6. N-terminal carboxyl and tetrazole-containing amides as adjuvants to Grb2 SH2 domain ligand binding.
Burke TR; Yao ZJ; Gao Y; Wu JX; Zhu X; Luo JH; Guo R; Yang D
Bioorg Med Chem; 2001 Jun; 9(6):1439-45. PubMed ID: 11408162
[TBL] [Abstract][Full Text] [Related]
7. From consensus sequence peptide to high affinity ligand, a "library scan" strategy.
Yeh RH; Lee TR; Lawrence DS
J Biol Chem; 2001 Apr; 276(15):12235-40. PubMed ID: 11278862
[TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of small chemical inhibitors containing different scaffolds for lck SH2 domain.
Park SH; Kang SH; Lim SH; Oh HS; Lee KH
Bioorg Med Chem Lett; 2003 Oct; 13(20):3455-9. PubMed ID: 14505648
[TBL] [Abstract][Full Text] [Related]
9. Binding, domain orientation, and dynamics of the Lck SH3-SH2 domain pair and comparison with other Src-family kinases.
Hofmann G; Schweimer K; Kiessling A; Hofinger E; Bauer F; Hoffmann S; Rösch P; Campbell ID; Werner JM; Sticht H
Biochemistry; 2005 Oct; 44(39):13043-50. PubMed ID: 16185072
[TBL] [Abstract][Full Text] [Related]
10. Conformationally constrained phosphotyrosyl mimetics designed as monomeric Src homology 2 domain inhibitors.
Burke TR; Barchi JJ; George C; Wolf G; Shoelson SE; Yan X
J Med Chem; 1995 Apr; 38(8):1386-96. PubMed ID: 7537333
[TBL] [Abstract][Full Text] [Related]
11. Structure-based design of an osteoclast-selective, nonpeptide src homology 2 inhibitor with in vivo antiresorptive activity.
Shakespeare W; Yang M; Bohacek R; Cerasoli F; Stebbins K; Sundaramoorthi R; Azimioara M; Vu C; Pradeepan S; Metcalf C; Haraldson C; Merry T; Dalgarno D; Narula S; Hatada M; Lu X; van Schravendijk MR; Adams S; Violette S; Smith J; Guan W; Bartlett C; Herson J; Iuliucci J; Weigele M; Sawyer T
Proc Natl Acad Sci U S A; 2000 Aug; 97(17):9373-8. PubMed ID: 10944210
[TBL] [Abstract][Full Text] [Related]
12. Tyr
Borowicz P; Sundvold V; Chan H; Abrahamsen G; Kjelstrup H; Nyman TA; Spurkland A
J Immunol; 2021 Aug; 207(4):1128-1137. PubMed ID: 34321230
[TBL] [Abstract][Full Text] [Related]
13. Thermodynamics of phosphotyrosine peptide-peptoid hybrids binding to the p56lck SH2 domain.
Dekker FJ; Mol NJ; Liskamp RM
J Pept Sci; 2010 Jul; 16(7):322-8. PubMed ID: 20552566
[TBL] [Abstract][Full Text] [Related]
14. Structure-based design of peptidomimetic antagonists of p56(lck) SH2 domain.
Hobbs CJ; Bit RA; Cansfield AD; Harris B; Hill CH; Hilyard KL; Kilford IR; Kitas E; Kroehn A; Lovell P; Pole D; Rugman P; Sherborne BS; Smith IE; Vesey DR; Walmsley DL; Whittaker D; Williams G; Wilson F; Banner D; Surgenor A; Borkakoti N
Bioorg Med Chem Lett; 2002 May; 12(10):1365-9. PubMed ID: 11992778
[TBL] [Abstract][Full Text] [Related]
15. Phosphotyrosine-containing dipeptides as high-affinity ligands for the p56lck SH2 domain.
Llinaś-Brunet M; Beaulieu PL; Cameron DR; Ferland JM; Gauthier J; Ghiro E; Gillard J; Gorys V; Poirier M; Rancourt J; Wernic D; Betageri R; Cardozo M; Jakes S; Lukas S; Patel U; Proudfoot J; Moss N
J Med Chem; 1999 Feb; 42(4):722-9. PubMed ID: 10052978
[TBL] [Abstract][Full Text] [Related]
16. Synthesis of a new conformation-constrained L-tyrosine analogue as a potential scaffold for SH2 domain ligands.
Liu F; Zha HY; Yao ZJ
J Org Chem; 2003 Aug; 68(17):6679-84. PubMed ID: 12919032
[TBL] [Abstract][Full Text] [Related]
17. Crystal structures of the human p56lck SH2 domain in complex with two short phosphotyrosyl peptides at 1.0 A and 1.8 A resolution.
Tong L; Warren TC; King J; Betageri R; Rose J; Jakes S
J Mol Biol; 1996 Mar; 256(3):601-10. PubMed ID: 8604142
[TBL] [Abstract][Full Text] [Related]
18. The phosphopeptide-binding specificity of Src family SH2 domains.
Payne G; Stolz LA; Pei D; Band H; Shoelson SE; Walsh CT
Chem Biol; 1994 Oct; 1(2):99-105. PubMed ID: 9383377
[TBL] [Abstract][Full Text] [Related]
19. Design of tetrapeptide ligands as inhibitors of the Src SH2 domain.
Nam NH; Pitts RL; Sun G; Sardari S; Tiemo A; Xie M; Yan B; Parang K
Bioorg Med Chem; 2004 Feb; 12(4):779-87. PubMed ID: 14759738
[TBL] [Abstract][Full Text] [Related]
20. The human immunodeficiency virus type 1 Nef protein binds the Src-related tyrosine kinase Lck SH2 domain through a novel phosphotyrosine independent mechanism.
Dutartre H; Harris M; Olive D; Collette Y
Virology; 1998 Aug; 247(2):200-11. PubMed ID: 9705913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
